Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 7.96%153.58B | 0.99%92.33B | -6.63%40.02B | 16.73%202.2B | 19.04%142.25B | 30.66%91.43B | 47.60%42.86B | 26.12%173.21B | 20.13%119.5B | 12.61%69.97B |
| Operating income | 7.96%153.58B | 0.99%92.33B | -6.63%40.02B | 16.73%202.2B | 19.04%142.25B | 30.66%91.43B | 47.60%42.86B | 26.12%173.21B | 20.13%119.5B | 12.61%69.97B |
| Operating expenses | -10.08%-125.33B | -2.96%-75.36B | 4.86%-32.88B | -14.79%-162.75B | -17.39%-113.85B | -25.80%-73.19B | -41.79%-34.56B | -28.02%-141.77B | -21.74%-96.98B | -14.72%-58.18B |
| Gross profit | -0.50%28.26B | -6.92%16.97B | -14.00%7.14B | 25.47%39.45B | 26.11%28.4B | 54.66%18.24B | 77.89%8.3B | 18.19%31.44B | 13.66%22.52B | 3.24%11.79B |
| Selling expenses | -55.52%-7.95B | -63.31%-5.04B | -61.56%-2.3B | -7.47%-7.83B | -0.09%-5.11B | 5.22%-3.08B | 2.28%-1.42B | -24.00%-7.29B | -32.53%-5.11B | -46.80%-3.25B |
| Administrative expenses | 4.50%-2.88B | 5.92%-1.89B | 6.80%-937.96M | -0.45%-4.76B | 2.39%-3.02B | 2.80%-2.01B | 5.11%-1.01B | 3.24%-4.74B | 10.61%-3.09B | 6.43%-2.07B |
| Research and development expenses | -6.86%-6.64B | -1.12%-4.24B | 2.88%-1.91B | -15.27%-9.28B | -12.87%-6.21B | -19.47%-4.19B | -27.94%-1.96B | -24.97%-8.05B | -16.88%-5.5B | -10.48%-3.51B |
| Profit from asset sales | 641.00%97.96M | 280.24%31.39M | 79.38%-3.72M | 4,750.53%4.83M | -394.07%-18.11M | -708.25%-17.41M | -121.58%-18.03M | -97.95%99.59K | 92.06%-3.66M | 93.16%-2.15M |
| Revaluation surplus | 1,262.07%106.98M | -13.88%60.01M | -338.32%-71.53M | 263.21%42.49M | -113.17%-9.21M | 152.62%69.68M | -36.06%30.01M | -151.72%-26.04M | -61.42%69.88M | -8.63%-132.42M |
| -Changes in the fair value of other assets | 1,262.07%106.98M | -13.88%60.01M | -338.32%-71.53M | 263.21%42.49M | -113.17%-9.21M | 152.62%69.68M | -36.06%30.01M | -151.72%-26.04M | -61.42%69.88M | -8.63%-132.42M |
| Impairment and provision | -14.16%-406.1M | -16.98%-258.18M | -298.91%-227.13M | -40.68%-773.85M | 8.66%-355.71M | 30.73%-220.7M | 68.11%-56.94M | -51.62%-550.08M | -270.15%-389.43M | -277.12%-318.59M |
| -Other impairment is provision | -14.16%-406.1M | -16.98%-258.18M | -298.91%-227.13M | -40.68%-773.85M | 8.66%-355.71M | 30.73%-220.7M | 68.11%-56.94M | -51.62%-550.08M | -270.15%-389.43M | -277.12%-318.59M |
| Special items of operating profit | 2.56%3.62B | 25.23%3.2B | -54.91%606.68M | 101.06%4.57B | 158.94%3.53B | 185.14%2.56B | 228.65%1.35B | 49.39%2.27B | 23.21%1.36B | 5.79%896.34M |
| Operating profit | -31.90%8.21B | -34.98%5.17B | -81.30%695.16M | 98.05%14.01B | 114.13%12.06B | 693.72%7.95B | 6,438.25%3.72B | 29.13%7.08B | 6.24%5.63B | -57.74%1B |
| Financing cost | 752.96%1.56B | 992.89%1.69B | 1,178.12%1.03B | -172.41%-91.16M | 13.53%-239.26M | -30.76%154.79M | -695.32%-95.39M | -94.94%125.89M | -110.08%-276.69M | -92.38%223.57M |
| Adjustment items of earning before tax | -3.80%174.14M | -8.29%142.35M | 1.87%127.78M | -41.82%362.53M | -26.73%181.03M | -7.00%155.22M | -5.60%125.43M | -25.78%623.09M | -67.28%247.08M | -70.36%166.9M |
| Earning before tax | -17.10%9.95B | -15.22%7B | -50.61%1.85B | 82.56%14.28B | 114.22%12B | 493.38%8.26B | 5,923.95%3.75B | -11.16%7.82B | -36.35%5.6B | -76.27%1.39B |
| Tax | 17.92%-1.31B | 44.55%-667.11M | 81.08%-100.2M | -98.56%-1.59B | -164.60%-1.6B | -3,964.34%-1.2B | -567.00%-529.68M | -44.69%-801.24M | 7.20%-604.98M | 89.20%-29.6M |
| After-tax profit from continuing operations | -16.97%8.63B | -10.22%6.34B | -45.59%1.75B | 80.73%12.69B | 108.12%10.4B | 417.98%7.06B | 1,732.43%3.22B | -14.90%7.02B | -38.68%5B | -75.63%1.36B |
| Earning after tax | -16.97%8.63B | -10.22%6.34B | -45.59%1.75B | 80.73%12.69B | 108.12%10.4B | 417.98%7.06B | 1,732.43%3.22B | -14.90%7.02B | -38.68%5B | -75.63%1.36B |
| Minority profit | ---- | ---- | ---- | -81.23%235.16K | -55.19%1.05M | -40.19%825.49K | -140.86%-575.91K | 109.47%1.25M | 120.74%2.35M | 116.01%1.38M |
| Profit attributable to shareholders | -16.97%8.63B | -10.21%6.34B | -45.60%1.75B | 80.76%12.69B | 108.20%10.4B | 418.45%7.06B | 1,747.58%3.22B | -15.06%7.02B | -38.79%4.99B | -75.69%1.36B |
| Basic earnings per share | -17.21%1.01 | -10.84%0.74 | -44.74%0.21 | 81.71%1.49 | 106.78%1.22 | 418.75%0.83 | 1,800.00%0.38 | -9.89%0.82 | -33.71%0.59 | -73.77%0.16 |
| Diluted earnings per share | -17.21%1.01 | -10.84%0.74 | -44.74%0.21 | 81.71%1.49 | 106.78%1.22 | 418.75%0.83 | 1,800.00%0.38 | -9.89%0.82 | -32.95%0.59 | -73.33%0.16 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Deloitte Huayong Certified Public Accountants Ltd | -- | -- | -- | Deloitte Huayong Certified Public Accountants Ltd | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.